批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2021/04/16 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2018/09/06 |
SUPPL-10(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2017/01/06 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2015/02/20 |
SUPPL-8(补充) |
Approval |
Efficacy |
PRIORITY
|
|
|
2014/10/29 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/06/02 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2014/01/21 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2013/03/26 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/11/19 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2012/08/10 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/05/01 |
ORIG-1(原始申请) |
Approval |
Type 4 - New Combination |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
活性成分:AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE 剂型/给药途径:SPRAY, METERED;NASAL 规格:0.137MG/SPRAY;0.05MG/SPRAY 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
202236 |
001 |
NDA |
DYMISTA |
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE |
SPRAY, METERED;NASAL |
0.137MG/SPRAY;0.05MG/SPRAY |
Prescription |
Yes |
No |
AB |
2012/05/01
|
MYLAN SPECIALITY LP |
207712 |
001 |
ANDA |
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE |
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE |
SPRAY, METERED;NASAL |
0.137MG/SPRAY;0.05MG/SPRAY |
Prescription |
No |
Yes |
AB |
2017/04/28
|
APOTEX |
208111 |
001 |
ANDA |
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE |
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE |
SPRAY, METERED;NASAL |
0.137MG/SPRAY;0.05MG/SPRAY |
Prescription |
No |
No |
AB |
2021/02/18
|
PADAGIS ISRAEL |